The total return over the past 12 months is +67.04% vs. +16.94% for the S&P 500. So far it's up +11.58% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +67.04% | +65.18% | +6.25% | +1.77% | (3.16%) | (3.94%) |
| Total Return CAGR | +67.04% | +65.18% | +6.25% | +1.77% | (3.16%) | (3.94%) |
| Revenue CAGR | +3.31% | +29.77% | +13.94% | +22.92% | N/A | +11.13% |
| Net Income CAGR | +229.08% | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | +221.86% | N/A | N/A | N/A | +18.40% | N/A |
| Free Cash Flow CAGR | +20.67% | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | +20.60% | N/A | +228.72% | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Rigel Pharmaceuticals, Inc. (RIGL)
| Year | Start price | End price | RIGL Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $42.83 | $47.79 | +11.58% | +14.51% | (2.93%) |
| 2025 | $16.82 | $42.83 | +154.64% | +17.72% | +136.92% |
| 2024 | $14.50 | $16.82 | +16.00% | +24.89% | (8.89%) |
| 2023 | $15.00 | $14.50 | (3.33%) | +26.19% | (29.52%) |
| 2022 | $26.50 | $15.00 | (43.40%) | (18.17%) | (25.23%) |
| 2021 | $35.00 | $26.50 | (24.29%) | +28.74% | (53.03%) |
| 2020 | $21.40 | $35.00 | +63.55% | +18.37% | +45.18% |
| 2019 | $23.00 | $21.40 | (6.96%) | +31.22% | (38.18%) |
| 2018 | $38.80 | $23.00 | (40.72%) | (4.56%) | (36.16%) |
| 2017 | $23.80 | $38.80 | +63.03% | +21.70% | +41.33% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
